VivoSeq
Gastroenterology

Carcinoid Syndrome

13

Pipeline Programs↗

1

Active Trials↗

11

Companies Involved↗

Carcinoid Syndrome is an emerging landscape with 13 programs across 11 companies. The most active players are Sun Pharma, Amgen, Novartis. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

40/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

47/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sun Pharma logo

Sun Pharma

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2Incyte logo

Incyte

1 program

Phase 2T

TerSera Therapeutics LLC

1 program

Phase 2A

Albireo, an Ipsen Company

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

14programs
Small molecule857%
Peptide429%
Monoclonal antibody214%

Modality classified for 93% of 15 pipeline programs.

Analysis

Trial Status

16

clinical trials

Completed7 · 44%
Withdrawn4 · 25%
Terminated4 · 25%
Recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors
Recruiting·CCrinetics Pharmaceuticals Inc.·Phase 3·NCT07087054·141 enrolled
Telotristat Etiprate for Carcinoid Syndrome Therapy
Completed·LLexicon Pharmaceuticals·Phase 3·NCT02063659·76 enrolled
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Completed·CCrinetics Pharmaceuticals Inc.·Phase 2·NCT05361668·36 enrolled
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Completed·LLexicon Pharmaceuticals·Phase 2·NCT00853047·23 enrolled
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Completed·LLexicon Pharmaceuticals·Phase 3·NCT01677910·135 enrolled
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Completed·LLexicon Pharmaceuticals·Phase 3·NCT02026063·124 enrolled
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Completed·Ipsen logoIpsen·Phase 3·NCT00774930·115 enrolled
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
Completed·LLexicon Pharmaceuticals·Phase 2·NCT01104415·15 enrolled
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Terminated·Ipsen logoIpsen·Phase 3·NCT00092287·4 enrolled
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
Terminated·Ipsen logoIpsen·Phase 2·NCT01018953·8 enrolled
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01886287·2 enrolled
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
Terminated·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 1/2·NCT00884715·10 enrolled
Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT04776876
Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
Withdrawn·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT04065165
Study of Panitumumab in the Treatment of Carcinoid Syndrome
Withdrawn·—·Phase 2·NCT01172717
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)